

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
January 8, 2024

CLEARPOINT NEURO, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

120 S. Sierra Ave., Suite 100
Solana Beach, CA 92075
(Address of principal executive offices, zip code)
(888) 287-9109
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2024, ClearPoint Neuro, Inc. (the “Company”) issued a press release announcing its preliminary, unaudited financial results for the fourth fiscal quarter ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On January 8, 2024, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	Press Release dated January 8, 2024
Exhibit 99.2	Investor Presentation dated January 8, 2024
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2024

CLEARPOINT NEURO, INC.

By: /s/ Danilo D'Alessandro

Danilo D'Alessandro

Chief Financial Officer



ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

SOLANA BEACH, CA, January 8, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2023. These preliminary unaudited financial results are management’s estimates and are subject to revision in the course of completing annual audit processes. Audited results for 2023 will be publicly reported by the Company later in the first quarter of 2024, prior to a Form 10-K filing for the year with full financial statements.

Fourth Quarter 2023 Preliminary Unaudited Financial Highlights

- Preliminary unaudited revenue of approximately \$6.8 million, a 32% year-over-year increase;
- Increased biologics and drug delivery revenue to approximately \$4.1 million, a 76% year-over-year increase; and
- Cash burn of approximately \$1.2 million in the fourth quarter. The Company had approximately \$23.1 million in cash and cash equivalents at December 31, 2023.

Full Year 2023 Preliminary Unaudited Financial Highlights

- Achieved preliminary unaudited record revenue of approximately \$24 million, a 17% year-over-year increase, versus most recent guidance of \$23 - \$25 million; and
- Increased biologics and drug delivery revenue to approximately \$13.6 million, a 49% year-over-year increase.

Business Outlook and Planned Value Creating Milestones

- The Company estimates revenue in 2024 to be between \$28 million and \$32 million, representing growth between 17% and 33%;
 - Achieve FDA clearance and launch SmartFrame OR for navigation and first revenue in the operating room;
 - Launch full market release of the ClearPoint PRISM[®] Neuro Laser Therapy System;
 - Launch and deploy ClearPoint 2.2 Software with embedded ClearPoint Maestro[®] and 1.2 Array Software with parallel trajectory tumor planning application to the installed base;
 - Win first purchase orders for GLP ready pre-clinical services;
 - Prototype demonstration of next generation software application for AI predictive modeling to pharma partners;
 - Continue global expansion to achieve 100 ClearPoint sites by 2025; and
 - Demonstrate operating leverage with expenses increasing less than revenue growth.
-

“We are thrilled with our fourth quarter performance delivering record revenue of \$6.8 million, reflecting 32% growth, while meaningfully reducing our cash burn and gaining commitments for multiple new ClearPoint installations,” commented Joe Burnett, President and CEO at ClearPoint Neuro.

“In 2024, we look forward to several new product introductions reflecting success with the strategic investments we have made to expand our leadership position, including the SmartFrame OR for our entrance into the operating room; the full market release of the PRISM laser therapy system; the integration of ClearPoint Maestro into our navigation software; and the expansion of our pre-clinical biologics and drug delivery services including GLP readiness. These represent four new potential revenue streams that we plan to add to our base business throughout the year.”

Management will be available for meetings in San Francisco during the J.P. Morgan Healthcare Conference from January 8-11, 2024.

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

This press release contains forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results. These forward-looking statements are based on management’s current expectations and are subject to the risks inherent in the business, which may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s products and services; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their delivery of therapies; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2023, both of which have been filed with the Securities and Exchange Commission, and the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which the Company intends to file with the Securities and Exchange Commission on

or before March 31, 2024. The Company does not assume any obligation to update these forward-looking statements.

Contact:

Danilo D'Alessandro, Chief Financial Officer

(888) 287-9109

ir@clearpointneuro.com



CLEARPOINT®
NEURO

WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.™

Nasdaq: CLPT

January 2024



This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company's expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results. These forward looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and the Company's Quarterly Reports on Form 10-Q for the three months ended September 30, 2023, both of which the Company filed with the Securities and Exchange Commission, and the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2024. We do not assume any obligation to update these forward-looking statements.



CLEARPOINT[®]


NEURO

Our Company

We Are a Device, Cell and Gene Therapy-
Enabling Company, Offering Precise Navigation
to the Brain and Spine

We Uniquely Provide Both Established Clinical
Products as well as Pre-Clinical Development
Services for Controlled Drug and Device Delivery

A Precision Navigation Company Supporting...



50+ Biotech & Pharma Partners:

- Drug Navigation, Combination-Infusion Devices, A.I. Monitoring Solutions
- Established Quality System and Custom Device Development
- Translational Pre-Clinical, Clinical Trial & Regulatory Services



100+ Global Neurosurgeons:

- Expanding Navigation Systems for both the MRI & Operating Room
- An FDA Cleared Second-Generation Laser Therapy System
- 20+ Global Specialists Providing On-Site Training & Quality Control



Built On a Strong Foundation:

- 20,000 sq. ft. Manufacturing, R&D Lab
- Regulatory Approvals (FDA, CE, more)
- Established, Audited Quality System
- More than 100 Issued Patents*
- 10 Years of Revenue, 6,000+ Procedures


A \$12B+ TAM Diversified Across 35+ Indications and 50+ Partners

*Including owned and licensed patents

Our Company

The ClearPoint® Neuro Navigation System


Leverage live MR Imaging to **Decide, Guide, and Confirm** with sub-millimetric accuracy



Pre-Plan Trajectory and
Decide Entry Point



Automatically **Guide** Precision
Adjustments Prior to Insertion



Confirm Quality of Delivery
Into Permanent Record

Our Company

The ClearPoint® Neuro Navigation System: *10+ Years of Experience*

Capital Hardware and Software



ClearPoint Neuro
Navigation
Software v.2.1



Inflexion® Head
Fixation Frame



ClearPoint
Array
Software
v.1.2



Multi-Positional
Head Fixation
Frame



MRI Monitor




ClearPoint
Maestro®
Brain Model



MRI Coils



Disposables



SmartFrame® XG with
Skull Mount Base



Accessory Kit (4Fr, 5Fr, and 7Fr Available)



SmartFrame Array®
Kit Components

A Strong Foundation

Key Products: **FDA** **CE** Marked Platforms

HEADQUARTERS

Solana Beach, CA

MANUFACTURING

Carlsbad, CA

2024 REVENUE GUIDANCE

\$28 m - \$32 m^(A)

CASH & CASH EQUIVALENTS

\$23.1 m^(B)

PATENTS ISSUED

100+^(C)

GROSS MARGIN

60%^(D,E)

EMPLOYEES


100+

QUALITY SYSTEM

MD-SAP

(A) Estimated and subject to revision
(B) Unaudited as of, and for the quarter ended December 31, 2023
(C) Including owned and licensed patents
(D) For the Trailing Twelve Months (TTM)
(E) Unaudited as of, and for the quarter ended September 30, 2023

10 Years of Continued Product Sales and Revenue Growth



Our Company

A Strong Foundation

- 1,500 sq. ft Class 8 Clean Room with Expansion Capability
- 1,300 sq. ft Dedicated R&D Lab Space
- ISO 13485/MDSAP/EU MDR Certified Quality System
- Successful Audit Outcomes from Global Regulatory Bodies and Pharma
- Training Facility with over 100 Surgeons and Pharma Scientist Visitors



© 2024 CLEARPOINT NEURO

8

A Therapy Enabling Platform

75+ Centers in the US, EU, UK, China, Brazil, and Canada

UC San Francisco
Stanford University
Lucile Packard Children's Hospital
Benioff Children's Hospital
San Francisco VA
USC Keck Hospital
UC San Diego
Mayo Clinic in Arizona
University of Colorado
University of Utah
Cook Children's Hospital
Texas Children's Hospital
MD Anderson Cancer Center
Houston Methodist Hospital
Univ. Kansas Medical Center
Dallas Presbyterian Hospital
Cincinnati Jewish Hospital
Children's National Hospital
Banner Health Tucson
Ohio State University
University of Oklahoma Medical Center
Methodist Hospital San Antonio
Barnes-Jewish Hospital
Froedtert Hospital
UT Southwestern Medical Center
Baptist Medical Center Jacksonville
Henry Ford Health

University of Wisconsin
University of Michigan
University of Minnesota
Northwestern Central DuPage
Nationwide Children's
Cincinnati Children's Hospital
Riverside Methodist Hospital
University of Virginia
INOVA Fairfax
Carilion Clinic
JFK University Medical Center

Charles River Labs – Laval
Charles River Labs – Mattawan
Children's Mercy Hospital
Hos. Univ. of Pennsylvania
University of Alabama at Birmingham
CHOA Scottish Rite
Children's Hospital of Alabama
Mayo Clinic in Florida
Oschner Medical Center
Emory University
Duke University

Rigshospitalet (Copenhagen, Denmark)
Mazowiecki Szpital Bródnowski (Warsaw, Poland)
Hôpital Fondation Rothschild (Paris, France)
TIDU GENOV - Institut du Cerveau (Paris, France)
Skånes Universitetssjukhus Lund (Lund, Sweden)
Sahlgrenska Universitetssjukhuset (Gothenburg, Sweden)
University Hospital of Wales (Cardiff, United Kingdom)
Universitätsklinikum Düsseldorf (Düsseldorf, Germany)
Universitätsklinikum Freiburg (Freiburg, Germany)
Policlinico Umberto I (Rome, Italy)
Hospital Israelita Albert Einstein (São Paulo, Brazil)
Charles River Labs (Lyon, France)
Prisys Biotechnologies (Shanghai, China)
Kaleida Health
Mt. Sinai West
Yale University
Weill Cornell
Johns Hopkins University
Boston Children's Hospital
Massachusetts General Hospital
Brigham & Women's
National Institutes of Health
Memorial Sloan-Kettering
Dartmouth-Hitchcock
Beth Israel Deaconess
Children's Hospital of Philadelphia
Hackensack Univ. Med. Center
Tampa General Hospital

100+
Centers
Expected
by 2025

The ClearPoint Platform has been used in over 6,000 procedures

1

Biologics & Drug Delivery*



...with 50+ industry and academic partners

2

Navigation for DBS



3






























Laser Therapy




ClearPoint Navigation is Compatible with all Major
Diagnostic and Intraoperative MRI Scanners




~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications*

ESTIMATED LAUNCH SEQUENCE	Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Therapy	Incremental Revenue from Annual Incidence
	Parkinson's Disease	1,000,000 ¹	60,000 ¹	 			\$270 M - \$1.35 B
	Drug Resistant Epilepsy	1,000,000 ²	11,000 ³	 			\$49.5 M - \$198 M
	Refractory Essential Tremor	3,500,000 ⁴	60,000 ⁵				\$180 M - \$1.08 B
	Brain Tumors (n=3) ⁶	35,000 ^{7,8}	13,300 ^{7,8}	 			\$33.3 M - \$300 M
	Severe Obsessive-Compulsive Disorder	500,000 ^{9,10}	10,000 ^{9,10}				\$45 M - \$75 M
	Dystonia	250,000 ¹¹	8,000 ¹²				\$36 M - \$60 M
	Rare Genetic/Lysosomal (n=7) ¹³	36,500 ¹⁴⁻¹⁸	3,000 ^{14,19,20}	 			\$13.5 M - \$67.5 M
	Paralysis / Spinal Cord (n=15) ^{21,22}	331,000 ²²⁻²⁴	17,900 ²³	 			\$80.6 M - \$403 M
	Huntington's Disease	30,000 ²⁵	4,000 ²⁵	 			\$18 M - \$90 M
	Alzheimer's Disease	6,000,000 ²⁶	500,000 ²⁶	 			\$1.5 B - \$11.3 B
	Severe Major Depressive Disorder	1,000,000 ¹⁰	20,000 ^{10,27}				\$90 M - \$150 M
	Stroke Rehabilitation	2,000,000 ²⁸	610,000 ²⁸				\$1.83 B - \$5.49 B
	Frontotemporal Dementia	60,000 ²⁹	12,000 ²⁹				\$54 M - \$270 M
							\$4.2 B - \$20.8 B

 Commercial U.S or EU ClearPoint procedures today

 Active clinical trial

 Pre-clinical study/testing


Citations & Footnotes

1. "Parkinson's Disease Statistics," Parkinson's News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older>
2. Neuron Therapeutics. (2021 November 4). *Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021_11_01_INDclearance_FINALVersion.pdf
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. "About DIPG/DMG," DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. "Multiple System Atrophy," Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. "Spinocerebellar ataxia type 3," Orphanet, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf
18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. "Aromatic L-Amino Acid Decarboxylase Deficiency," National Organization for Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montañó AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. "Huntington's Disease," *Mov Disord.* 2019 Jun; 34(6): 858–865.
26. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>
27. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
28. "Stroke Facts," Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
29. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

Our Company


4 Pillar Growth Strategy by 2025

Development Pipeline Over the Next Two Years



New Product Growth Drivers Expected in 2024

1 Biologics & Drug Delivery




ClearPoint Orchestra™ Head Fixation Frame



Spinal Infusion Anchoring Devices

Radially Branching Cell therapy Devices

2 Navigation for DBS



ClearPointer™ and SmartFrame O.R.
FDA 510(k) Pending



ClearPoint 2.2 Software w/ Embedded
ClearPoint Maestro®

3 Laser Therapy




PRISM 3.0 T & 1.5 T Compatible Systems
(1.5 T Compatibility not yet FDA Cleared)



Array 1.2 Parallel Trajectory Tumor Feature

A.I. Powered 'Maestro' Brain Model

- FDA Cleared, Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects
 - Auto-Segmentation for Device Targeting
 - Direct Navigation in Clinical Trials for Drug Delivery
 - Longitudinal Comparison for Pharma Trial follow-up
- **Platform Engine** for future navigation tools for Drug Delivery, DBS, BCI, Biopsy and Laser Therapy
- Expandable to CT Guidance in the Operating Room



Executive Summary



Unique platform technology

with 10+ years of commercial experience enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Expandable Platform

through advanced A.I. and machine learning software applications and strategic partnerships



Total potential addressable market

> \$12B for our products, pipeline and partnerships



Pipeline of new revenue streams

through the expansion into the Operating Room, Launch of our own PRISM Laser Therapy, Maestro Brain Model Deployment and addition of pre-clinical services and capacity including GLP



Large, growing number of customer and partner sites

of 75+ leading Neurosurgery and research centers worldwide, on pace to be in 100+ by 2025



A growing and passionate team

of embedded scientists and specialists





CLEARPOINT[®]
NEURO



